Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 807 results for "herceptin"

Roche Loses A Little Luster Before Year-End

Summary The Phase III MARIANNE study of Kadcyla delivered a major disappointment as this would-be successor to Herceptin failed to show superior efficacy alone or in combination with Perjeta. Roche also announced the end of another Alzheimer's ... Seeking Alpha, 7 hours ago

22 images for herceptin

Med India, 5 days ago
FiercePharma, 3 days ago
Medical News Today, 6 days ago
Newswise, 1 week ago
OncLive, 1 week ago
MedPage Today, 1 week ago
Seeking Alpha, 1 week ago
Proactive Investors Australia, 3 weeks ago
GlobeNewswire, 1 month ago
RTTNews.com, 2 months ago
MedIndia

Targeted treatment herceptin found to greatly improve long-term survival of her2-positive breast cancer patients

VCU Massey Cancer Center physician-researcher Charles E. Geyer, Jr., M.D., was the National Protocol Officer for one component of a large national study involving two National Cancer Institute (NCI)-supported clinical trials that demonstrated that ...
 Science Daily3 days ago Herceptin found to improve long-term survival of HER2-positive breast cancer patients  EurekAlert!1 week ago A New World of Targeted Therapies for HER2-Positive Breast Cancer Takes Shape  HCPLive5 days ago Herceptin Improves Long-Term Survival of HER2-Positive Breast Cancer Patients  MedIndia6 days ago
[x]  

PBAC calls time on Herceptin program

 Pharma In Focus1 day ago

Unlocking Herceptin's potential against esophageal cancer

The protein HER2 is most commonly associated with breast cancer, but it also plays a role in several other cancers — including esophageal cancer. Using this knowledge and the drug trastuzumab (Herceptin), which targets HER2, City of Hope ...
 City of Hope1 day ago
FiercePharma

Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data

Roche ($RHHBY) has been riding high on the success of its newly augmented breast cancer franchise, charting promising numbers for standout drugs Kadcyla and Perjeta. But the company faced a stinging setback Friday. The next-gen duo failed to beat ...
 FiercePharma3 days ago
Pharma Letter

Novartis' Afinitor trial does not demonstrate statistical significance in HER2-positive breast cancer

Swiss pharma major Novartis (NOVN: VX) says that its BOLERO-1 trial of Afinitor (everolimus) in combination with Herceptin (trastuzumab) and paclitaxel as first-line treatment in HER2-positive advanced breast cancer did not demonstrate statistically ...
 Pharma Letter1 week ago Everolimus Does Not Overcome Trastuzumab Resistance  Medscape6 days ago Mixed bag for Novartis and Astellas in breast cancer  Pharmafocus1 week ago Novartis' bid to widen Afinitor's breast cancer reach falls short in PhIII  FiercePharma1 week ago
[x]  
MedPage Today

One For Choosing Wisely in Breast Cancer

A study presented at the San Antonio Breast Cancer Symposium showed that Herceptin may not complement chemotherapy in breast tumors with a high level of immune
 HCPLive1 week ago Forum Post: Re Herceptin trial  Macmillan Cancer Support1 week ago Herceptin May Be of Little Use in Immune Cell-Heavy Breast Ca  MedPage Today1 week ago

Forum Post: RE: Re Herceptin trial

Hi Shaz, I'm on Herceptin and was offered the chance to take part in the trial but chose not to. I wanted to have the Herceptin for the full year even though the trial is to find out if 6 months is sufficient. You are not just automatically entered ...
 Macmillan Cancer Support1 week ago Blog Post: Why Chemo and Herceptin together?  Macmillan Cancer Support2 weeks ago

PDL BioPharma's Q4 Revenues to Rise Y/Y on Higher Royalties - Analyst Blog

The anticipated rise in royalty revenues primarily emanates from higher third quarter sales of Avastin (up 5%), Herceptin (up 9%), Kadcyla (up 90%), Actemra (up 44%), Tysabri (up 24%) and Perjeta (up 213%) for which PDL BioPharma will receive ...
 Nasdaq1 week ago

Emperor of maladies, plethora of problems

Lack of awareness, inadequate and expensive treatment facilities and insurance claim rejections are the main reasons why cancer is a nightmare for patients and their caregivers, according to a panel of experts. Early detection is crucial when ...
 Calcutta Telegraph2 hours ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less